Journal: Biomolecules & Therapeutics
Article Title: Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis
doi: 10.4062/biomolther.2026.019
Figure Lengend Snippet: Overview of the immunopathogenesis and therapeutic targets of psoriasis. Epidermal damage triggers innate immune activation, promoting dendritic cell-mediated production of IL-23 and IL-12, which induce Th17- and Th1-dependent inflammatory responses, respectively. IL-17A and IL-17F subsequently act on keratinocytes via the IL-17 receptor complex, leading to keratinocyte activation and epidermal hyperplasia. Current injectable biologics (blue) and non-injectable small molecules or peptide inhibitors (red) targeting the IL-23/IL-17 axis are illustrated. pDC, plasmacytoid dendritic cell; mDC, myeloid dendritic cell.
Article Snippet: , Izokibep/ABY-035 , IL-17A affibody , PsO, PsA , SC , , Phase 2 completed/ NCT03591887 (PsO) Phase 2b/3 terminated/ NCT05623345 (PsA).
Techniques: Biomarker Discovery, Activation Assay